Table 3.
Post hoc analyis- nonsuperiority of combination versus monotherapy over time
| Parameter | EPO±GCSF (n = 8) | EPO (n = 8) | GCSF (n = 8) | ANOVA F test |
|---|---|---|---|---|
| LVEF (%) | ||||
| Baseline | 56.8 (1.3) | 57.7 (0.8) | 56.6 (0.6) | NS |
| 1 Week post MIa | 41.1 (1.6)* | 43.8 (0.7)* | 42.8 (1.5)* | NS |
| 6 Weeks post MIa | 41 (1.2)* | 39.3 (2.5)*, *** | 38.4 (2.1)*, *** | NS |
| Repeated measures ANOVA (main effect) | p < 0.01 | p < 0.01 | p < 0.01 | |
| LVEDV (mL) | ||||
| Baseline | 53.2 (0.9) | 53.2 (2) | 49.6 (1.2) | NS |
| 1 Week post MIa | 62.5 (1.5)* | 63.5 (2.5)* | 60.7 (2.1)* | NS |
| 6 Weeks post MIa | 67.9 (2)*, ** | 70.8 (2.1)*, *** | 70.5 (1.7)*, *** | NS |
| Repeated measures ANOVA (main effect) | p < 0.01 | p < 0.01 | p < 0.01 | |
| LVESV (mL) | ||||
| Baseline | 22.9 (0.9) | 22.6 (0.9) | 21.3 (0.4) | NS |
| 1 Week post MIa | 36.8 (1.2)* | 35.6 (1.6)* | 34.4 (1)* | NS |
| 6 Weeks post MIa | 40.7 (1.5)* | 43.1 (3.2)*, *** | 44 (2.3)*, *** | NS |
| Repeated measures ANOVA (main effect) | p < 0.01 | p < 0.01 | p < 0.01 | |
The values are expressed as the mean± by standard error (in parentheses)
LVEF left ventricle ejection fraction, LVEDV LV end-diastolic volume, LVESV LV end-systolic volume
NS Non significant
aChange from baseline value; significance of post-hoc test in repeated measures ANOVA design
*p < 0.01 vs. baseline, **p < 0.05 vs. 1 week, ***p < 0.01 vs. 1 week